Our recent in vitro study unveiled a promising approach in which the BRAF inhibitor encorafenib, although being a V600E/K-specific inhibitor, had synergistic effects when combined with binimetinib in NRAS-mutated melanoma cells in terms of increased viability reduction and apoptosis induction. Here, BRAF is linked to melanoma.